share_log

Boston Trust Walden Corp Acquires 2,521 Shares of STERIS Plc (NYSE:STE)

Boston Trust Walden Corp Acquires 2,521 Shares of STERIS Plc (NYSE:STE)

波士顿沃尔登信托公司收购STERIS公司(纽约证券交易所代码:STE)2521股
Financial News Live ·  2022/10/04 09:32

Boston Trust Walden Corp lifted its holdings in STERIS plc (NYSE:STE – Get Rating) by 1.1% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 235,891 shares of the medical equipment provider's stock after acquiring an additional 2,521 shares during the quarter. Boston Trust Walden Corp owned 0.24% of STERIS worth $48,629,000 at the end of the most recent quarter.

据波士顿信托华登公司在最近提交给美国证券交易委员会的文件中称,该公司在第二季度增持了STERIS公司的股份1.1%。该基金在本季度额外购买了2521股后,拥有这家医疗设备提供商的235,891股股票。截至最近一个季度末,波士顿信托沃尔登公司拥有STERIS 0.24%的股份,价值48,629,000美元。

Other hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of STERIS by 1.3% in the first quarter. Vanguard Group Inc. now owns 11,525,769 shares of the medical equipment provider's stock worth $2,786,586,000 after buying an additional 143,253 shares during the period. BlackRock Inc. increased its stake in shares of STERIS by 0.7% in the first quarter. BlackRock Inc. now owns 8,187,989 shares of the medical equipment provider's stock worth $1,979,609,000 after buying an additional 59,414 shares during the period. Massachusetts Financial Services Co. MA increased its position in STERIS by 1.9% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 4,363,147 shares of the medical equipment provider's stock valued at $1,054,878,000 after purchasing an additional 81,040 shares during the period. State Street Corp increased its position in STERIS by 0.4% during the 1st quarter. State Street Corp now owns 4,229,089 shares of the medical equipment provider's stock valued at $1,022,467,000 after purchasing an additional 17,292 shares during the period. Finally, Select Equity Group L.P. increased its position in STERIS by 7.0% during the 4th quarter. Select Equity Group L.P. now owns 1,712,380 shares of the medical equipment provider's stock valued at $416,810,000 after purchasing an additional 111,486 shares during the period. 92.04% of the stock is currently owned by institutional investors.

其他对冲基金最近也调整了在该公司的头寸。先锋集团第一季度增持了1.3%的STERIS股票。先锋集团现在持有这家医疗设备供应商11,525,769股股票,价值2,786,586,000美元,在此期间又购买了143,253股。贝莱德股份有限公司在第一季度增持了0.7%的STERIS股份。贝莱德股份有限公司目前持有这家医疗设备供应商8,187,989股股票,价值1,979,609,000美元,在此期间又购买了59,414股。马萨诸塞州金融服务公司在第一季度将其在STERIS的头寸增加了1.9%。马云目前持有这家医疗设备供应商4,363,147股股票,价值1,054,878,000美元,在此期间又购买了81,040股。道富银行在第一季度将其在STERIS的头寸增加了0.4%。道富集团目前持有这家医疗设备提供商4,229,089股股票,价值1,022,467,000美元,在此期间又购买了17,292股。最后,Select Equity Group L.P.在第四季度将其在STERIS的头寸增加了7.0%。SELECT Equity Group L.P.在此期间额外购买了111,486股票,现在拥有这家医疗设备提供商1,712,380股票,价值416,810,000美元。92.04%的股票目前由机构投资者持有。

Get
到达
STERIS
立体声
alerts:
警报:

STERIS Price Performance

Steris性价比

STE opened at $170.07 on Tuesday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.35 and a current ratio of 2.03. The stock has a market capitalization of $17.01 billion, a P/E ratio of 45.60, a P/E/G ratio of 1.78 and a beta of 0.82. The company's 50-day simple moving average is $200.35 and its two-hundred day simple moving average is $215.76. STERIS plc has a 52-week low of $160.08 and a 52-week high of $255.93.

STE周二开盘报170.07美元。该公司的负债权益比率为0.44,速动比率为1.35,流动比率为2.03。该股市值为170.1亿美元,市盈率为45.60倍,市盈率为1.78倍,贝塔系数为0.82。该公司50日简单移动均线切入位在200.35美元,200日简单移动均线切入位在215.76美元。Steris plc的52周低点为160.08美元,52周高点为255.93美元。

STERIS (NYSE:STE – Get Rating) last posted its earnings results on Tuesday, August 2nd. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.90. The business had revenue of $1.16 billion for the quarter, compared to analysts' expectations of $1.23 billion. STERIS had a net margin of 7.90% and a return on equity of 12.40%. As a group, analysts predict that STERIS plc will post 8.51 EPS for the current year.
Steris(纽约证券交易所代码:STE-GET评级)最近一次公布收益结果是在8月2日,星期二。这家医疗设备提供商公布本季度每股收益(EPS)为1.90美元,符合普遍预期的1.90美元。该业务当季营收为11.6亿美元,高于分析师预期的12.3亿美元。Steris的净利润率为7.90%,股本回报率为12.40%。分析师预计,作为一个整体,STERIS plc本年度每股收益将达到8.51欧元。

STERIS Increases Dividend

Steris增加股息

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 23rd. Stockholders of record on Wednesday, September 7th were paid a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 1.11%. The ex-dividend date was Tuesday, September 6th. This is a boost from STERIS's previous quarterly dividend of $0.43. STERIS's dividend payout ratio is 50.40%.

该公司最近还披露了季度股息,该股息于9月23日(星期五)支付。9月7日星期三,登记在册的股东获得了0.47美元的股息。这意味着年化股息为1.88美元,股息收益率为1.11%。除息日期为9月6日星期二。这是对STERIS之前季度派息0.43美元的提振。Steris的派息比率为50.40%。

Analyst Ratings Changes

分析师评级发生变化

A number of research analysts have issued reports on the stock. Needham & Company LLC downgraded shares of STERIS from a "buy" rating to a "hold" rating in a research report on Friday, September 23rd. KeyCorp dropped their price target on shares of STERIS from $256.00 to $240.00 and set an "overweight" rating on the stock in a research note on Thursday, August 4th. Piper Sandler began coverage on shares of STERIS in a research note on Thursday, July 14th. They issued an "overweight" rating and a $240.00 price target on the stock. StockNews.com upgraded shares of STERIS from a "hold" rating to a "buy" rating in a research note on Thursday, August 11th. Finally, TheStreet upgraded shares of STERIS from a "c+" rating to a "b" rating in a research note on Tuesday, August 2nd. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $252.00.

一些研究分析师已经发布了关于该股的报告。在9月23日星期五的一份研究报告中,Needham&Company LLC将STERIS的股票评级从“买入”下调至“持有”。8月4日,KeyCorp在一份研究报告中将其股票目标价从256.00美元下调至240.00美元,并对该股设定了“增持”评级。派珀·桑德勒在7月14日星期四的一份研究报告中开始报道STERIS的股票。他们对该股给予了“增持”评级和240.00美元的目标价。在8月11日星期四的一份研究报告中,StockNews.com将STERIS的股票评级从持有上调至买入。最后,华尔街在8月2日星期二的一份研究报告中将STERIS的股票评级从“c+”上调至“b”。一位研究分析师对该股的评级为持有,六位分析师对该公司的评级为买入。根据MarketBeat的数据,该公司目前的共识评级为“适度买入”,共识目标价为252.00美元。

STERIS Profile

立体轮廓

(Get Rating)

(获取评级)

STERIS plc provides infection prevention and other procedural products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.

Steris plc在全球范围内提供感染预防和其他程序产品和服务。它通过四个部门运作:医疗保健、应用消毒技术、生命科学和牙科。医疗保健部门提供清洁化学品和无菌保证产品;自动化内窥镜再处理系统和跟踪产品;用于胃肠道(GI)程序的配件、垫圈、消毒器和无菌加工部门运营的其他资本设备;以及直接在手术室使用的设备,包括手术台、灯和连接解决方案,以及设备管理服务。

See Also

另请参阅

  • Get a free copy of the StockNews.com research report on STERIS (STE)
  • Tyson Foods Takes a Lickin' and Keeps on Tickin' Lower
  • Small-Cap Catalyst Pharma Is Among Market's Best Price Performers
  • 3 Stocks Growing Their Businesses for 2023
  • China-Based EV Maker BYD Set For Big European, Japanese Expansion
  • Is Illumina Still the Gamechanger in Genomics Sequencing?
  • 免费获取StockNews.com关于STERIS的研究报告(STE)
  • 泰森食品股价下跌,继续走低
  • 小盘股Catalyst Pharma是市场上价格表现最好的公司之一
  • 2023年3只股票实现业务增长
  • 中国电动汽车制造商比亚迪将在欧洲和日本大举扩张
  • Illumina仍然是基因组测序中的Gamchanger吗?

Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.

接受STERIS日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对STERIS和相关公司的最新新闻和分析师评级的每日简要摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发